Skip to main content
MRUSinactive

Merus N.V.

Biopharma developer (SEC filing verified)·Commercial·Utrecht, Netherlands·CEO: Dr. Jan G.J. van de Winkel Ph.D.
OncologyRare DiseaseGene TherapyNeurologyImmunologyOphthalmologyCardiovascularInfectious DiseaseMetabolicRespiratoryPainDermatologyHematologyNephrologyMusculoskeletalGastroenterologyReproductivePsychiatry

MRUS evidence brief

What we can confirm

BioSniper Score:
8.5 / 10
Market Cap:
$6.83B
Lead Asset:
MCLA-129 (Phase 2)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Market Cap: $6.83B · Lead Asset: MCLA-129 (Phase 2)
BioSniper AIPage evidence connected

Prepared research question

What matters most for MRUS—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

8.5/10

BioSniper Score

Based on 3 of 6 signals

Limited data coverage

Market Cap

$6.83B

Cash Runway

—

Lead Asset

MCLA-129 (Phase 2)

Next Catalyst

—

Financial data as of Sep 30, 2025.

Tracking 4 pipeline candidates · 232 clinical trials · 1 FDA decision for Merus N.V..

Run Merus N.V. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Merus N.V. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 3 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial Health9.7

D/E 0.17 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is Merus N.V.'s lead drug candidate?

Merus N.V.'s most advanced tracked candidate is MCLA-129 (Phase 2) for Non-Small Cell Lung Cancer Metastatic.

Who is the CEO of Merus N.V.?

Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Merus N.V. (MRUS).

Where is Merus N.V. headquartered?

Merus N.V. (MRUS) is headquartered in Utrecht, Netherlands.

What therapeutic areas does Merus N.V. focus on?

Merus N.V. develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Reproductive, Psychiatry.

923 companies304,846 SEC filings22,682 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.